Physicians and patients expect that when medications are prescribed
correctly for labeled indications and are used as directed, these medications
generally will have beneficial effects and will not cause significant harm.
This confidence in pharmaceutical products reflects trust in the effectiveness
and integrity of the drug approval and monitoring process.
However, the current approval process for drugs and biological agents
in the United States has come under intense scrutiny, most notably because
of concerns about influence from industry. For instance, since adoption of
the 1992 Prescription Drug User Fee Act, which augmented the budget of the
Food and Drug Administration (FDA) by charging “user fees” to
pharmaceutical firms,1 the FDA has received
approximately $825 million in fees from drug and biologic manufacturers from
fiscal years 1993 through 2001.2- 3 During
that time, median approval times for standard (ie, “nonpriority”)
drugs decreased from 27 months in 1993 to 14 months in 2001, but as an inevitable
consequence of faster approvals, drug recalls following approval increased
from 1.56% for 1993-1996 to 5.35% for 1997-2001.2 In
addition, an investigation of 18 FDA expert advisory panels revealed that
more than half of the members of these panels had direct financial interests
in the drug or topic they were evaluating and for which they were making recommendations.4
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 103
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
With one exception, statins seemed to be relatively safe drugs. A cohort study comparing...
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.